Anthony J. Olszanski, MD, RPh, vice chair, Department of Hematology/Oncology, director, Early Drug Development Phase I Program, Fox Chase Cancer Center, discusses treatment advances in stage III melanoma.
Anthony J. Olszanski, MD, RPh
Advertisement
Articles by Anthony J. Olszanski, MD, RPh
Anthony J. Olszanski, MD, RPh, discusses the treatment selection process for use of cemiplimab in patients with cutaneous squamous cell carcinoma.
Advertisement
Latest Updated Articles
Dr. Olszanski Discusses Advances in Stage III MelanomaPublished: March 30th 2019 | Updated:
Dr. Olszanski on Patient Selection for Cemiplimab Treatment in CSCCPublished: March 24th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5